A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2018
At a glance
- Drugs LIK 066 (Primary)
- Indications Overweight; Polycystic ovary syndrome
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 09 Jul 2018 Status changed from recruiting to completed.
- 13 Jun 2018 Planned End Date changed from 18 May 2018 to 25 Jun 2018.